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ABSTRACT 
The main aim of nonmaterials is optimization on site of action at tumors cells as well least toxicity by its formulation. Only to 
progress the biodistribution of neoplasia drugs, nanoparticles are designed for optimal size and surface individuality to expand their 
flow time within the blood circulation. They are also proficient to carry their laden active drugs to cancer cells by using the single 
functional changes of tumors, as like their improved permeability and preservation result and the tumor microenvironment. In this 
study report, we have discussed the current status of nanoparticles developed as targeting delivery systems for anticancer drugs. 
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INTRODUCTION  
Nanotechnology is the study, design, creation, synthesis, 
manipulation, and application of materials, devices, and 
systems at the nanometer scale. The prefix nano is 
derived from the Greek word dwarf. One nanometer is 
equal to one billionth of a meter, that is, 10
−9
 m
1
. The 
importance of particles in this range is in the sense that 
they can have different and enhanced properties 
compared with the same material at a larger size. 
Increased surface area and quantum effects are two 
principal factors separating nonmaterial’s from other 
materials. These two factors can enhance properties such 
as reactivity, strength, electrical characteristics and in 
vivo behavior
2
. Nanotechnology and nanoscience are 
widely seen as having a great potential to bring benefits 
to many areas of research and applications
3
. The 
application of nanotechnology in the field of health care 
has come under great attention in recent times. There are 
many treatments today that take a lot of time and are 
also very expensive using nanotechnology, quicker and 
much cheaper treatments can be developed. Besides, 
there is another aspect to using nanotechnology in 
medicine. By using nanotechnology, the drug can be 
targeted to a precise location which would make the 
drug much more effective and reduce the chances of 
possible side-effects
4
. Cancer is one of the leading 
diseases and although there are many drugs available for 
treatment, using nanotech based approach increases the 
activity as well as reducing the side effects profile many 
fold
5
. In this study, we aim to discuss the nanotech 
based approach, especially the use of NPs and their 
various forms in anticancer drug delivery. 
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Figure 2: The relationship between nano-oncology and related fields
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LIMITATIONS OF CONVENTIONAL 
CHEMOTHERAPY 
Chemotherapy act as effectual drugs treatment designed 
to inhibit cancer cells or to slow the indictment or 
proliferation of these cells. Despite this advantage, the 
effect of conventional chemotherapy produces also 
several disadvantages. The conventional 
chemotherapeutic agents don't destroy only the cancer 
cells, they damage also the healthy cells causing organ 
dysfunction, myelosuppression (occurs the reduced 
production of white blood cells), alopecia (hair loss), 
mucositis (inflammation of the mucous membranes 
lining the digestive tract) etc.
8, 9
. Other disadvantages of 
these chemotherapeutics are that they remain in the 
circulation for a very short time and cannot interact with 
the cancerous cells and also the poor solubility of the 
drugs represents a problem because making them unable 
to penetrate the biological membranes
10
. 
In several studies, it was reported that a problem for the 
administered drugs is represented by the surface of the 
cancerous cells because the surface is covered with a 
multidrug resistance protein (P-glycoprotein) acting like 
a reflux pump which prevents the drug accumulation in 
the tumor. Because of their numerous disadvantages, the 
researchers tried to replace the conventional 
chemotherapeutic agents with nanoparticles
11-12
. 
CANCER NANOTECHNOLOGY  
Formal definitions of nanotechnological devices 
typically feature the requirements that the device itself 
or its essential components be man-made, and in the 1-1, 
00 nm range in at least one dimension. Cancer-related 
examples of nano-technologies include injectable drug 
delivery nanovectors such as liposomes for the therapy 
of breast cancer
13-14
; biologically targeted nanosized 
magnetic resonance imaging (MRI) contrast agents for 
intraoperative imaging in the context of neuro-
oncological interventions
15-16
; and novel, nanoparticle-
based methods for high-specificity detection of DNA 
and protein
17
. 
 
 
Figure 2 Biophysicochemical properties of NPs
18
. 
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Table 1: Types of organic nanoparticles for cancer therapy
19 
Type of NPs Size (nm) Advantages  Disadvantages  Applications 
Polymers 10-1000  
 
Biodegradability, drug 
release 
Low efficiency of 
delivery 
Delivery of 
components 
Quantum dots  <10  Surface modification Unstable at UV Detection of cancer 
Dendrimers  43952  High drugs carriage  Cytotoxic  Target Delivery 
Liposomes  50-100  Biodegradability  Inflammation  Gene delivery 
 
DRUG DESIGN IN NANOMEDICINE: 
CANCER THERAPHY 
Nanomedicine constructs are multicomponent systems, 
involving a carrier, therapeutic component, and often 
targeting moiety. Optimization of physicochemical 
properties of such constructs is challenging due to the 
interdependence of characteristics of individual 
components. Optimizing a construct (carrier þ drug 
molecule) as one unit and making this optimization part 
of an entire drug discovery process will allow 
nanotherapeutics to become a new class of drugs rather 
than being delivery vehicles for existing drugs
20
. This 
approach will bring greater flexibility to the design of 
APIs because drug properties (solubility, metabolism, 
bio-distribution, and target tissue accumulation) will 
reflect the combined properties of the drug molecule and 
nano-particle
21
. This will relax constraints on API 
chemical composition, as unfavorable physicochemical 
properties such as low plasma solubility, can be 
modified by association with the nano-particle. This 
streamlined nano-medicine development approach 
combined with preparation of high-throughput screening 
of large combinatorial libraries of nanoparticles with 
different properties is expected to produce a better path 
to nano-therapeutic optimization and should result in 
higher success rate of nanotherapeutics translation to 
clinical environment
22
. Recent works 
5
 demonstrated 
nanotherapeutic design optimization using screens of 
libraries containing up to 100 nanoparticle constructs 
with systematically varied physical and chemical 
properties, such as particle size, surface polyethylene 
glycol and ligand density, and drug release profile
23
. 
This library undergoes an iterative in vitro and in vivo 
screening process to optimize drug release, cell surface 
binding, pharmacokinetic/pharmacodynamic 
characteristics, biodistribution, and efficacy for a given 
indication. The broader use of such screening processes 
to include candidate APIs will lead to new classes of 
drugs along with well defined and possibly standardized 
processes of nanotherapeutic optimization
24
. Next-
Generation Nanoparticles and Systems Materials science 
will continue to produce new and more functional 
nanosystems that are responsive to changes in pH, 
temperature, and enzymatic environment and can 
recognize changes in physiology or in the state of the 
disease. Similarly, external triggers such as light or 
applied electromagnetic fields can also be used to 
activate nanoparticles. Exploitation of external or 
physiologic triggers will allow for more sophisticated 
nanoparticle designs and programmed drug release. 
Rational and personalized design of nanoparticles, 
including optimization of pharmacokinetics and tumor 
accumulation in coordination with drug release kinetics 
and matching targeting ligand type and density to tumor 
antigen profile, was also discussed as a path to 
improving nanoparticle drug delivery performance
25
. 
The value of nanoparticles capable of penetrating 
biologic barriers was acknowledged in discussions about 
nanoparticle vehicle design. Greater focus should be 
placed on overcoming biologic barriers such as tumor 
stroma, the blood–brain barrier, and vascular 
endothelium, which inhibit effective delivery of drugs to 
tumor tissue. Nanoparticle designs effectively 
facilitating alternate routes of oral or nasal delivery in 
addition to predominantly used systemic delivery were 
also of interest to the workshop participants. One new 
and exciting area discussed at the workshop was 
biomimetic nanoparticle design
26
. This has already 
proved helpful in the development of new families of 
therapeutic nanoparticles: "leukolike" and "plateloids," 
which have properties that reproduce features of biologic 
cells to delay uptake by the mononuclear phagocyte 
system and penetrate across vascular endothelia 
(leukolike) or adhere firmly to the target vascular 
surface (plateloids). Another bioinspired approach is the 
development of cooperative systems of nanoparticles 
that exploit host signaling networks to generate superior 
functionalities. A system relying on the coagulation 
signaling cascade resulting from deliberately inflicted 
tissue damage to recruit "clot-targeted" nanomedicines 
to the tumor was recently demonstrated 
6
. These systems 
demonstrate communication and bioresponsive 
capabilities that go well beyond the traditional design of 
contemporary nanoparticles for drug delivery
27
. 
TARGETED CANCER NANOTECHNOLOGY: 
THE CHALLENGES 
In an ideal scenario, the onset of the transformational 
processes leading towards malignancy would be 
detected early, as a matter of routine screening, by non-
invasive means such as proteomic pattern analysis from 
blood samples, or the in vivo imaging of molecular 
profiles and evolving lesion contours
28
. The biology of 
the host and the disease would be accurately determined, 
and dictate choices for targeting and barrier-avoiding 
strategies for intervention plan.Transforming cellular 
populations would be eradicated or contained, without 
collateral effects on healthy tissues, in a routine that 
could be repeated many times. Treatment efficacy would 
be monitored in real time. Therapeutics would be 
supplanted by personalized prevention. If fully 
integrated with the established cancer research 
enterprise, nanotechnology might help this vision 
become reality
29
. 
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FUTURE PROSPECTS 
Nanotechnology has become an enabling technology for 
personalized oncology, in which cancer detection, 
diagnosis and therapy are tailored to each individual’s 
tumor molecular profile, and for predictive oncology, in 
which genetic and/or molecular markers are used to 
predict disease development, progression and clinical 
outcomes. In recognition of its potential impact in cancer 
research, the US National Cancer Institute has recently 
funded eight national Centers of Cancer Nanotechnology 
Excellence
30
. Looking into the future, there are several 
research themes or directions that are particularly 
promising but require concerted effort for success. The 
first is the design and development of nanoparticles with 
monofunctions or multiple functions. For cancer and 
other medical applications, important functions include 
imaging (single or dual modality), therapy (a single drug 
or a combination of two or more drugs) and targeting 
(one or more ligands). Nanoparticles provide 
opportunities for designing and tuning properties that are 
not possible with other types of therapeutic drugs and 
have shown they have a bright future as a new 
generation of cancer therapeutics. Furthermore, the 
development of multifunctional nanoparticles might 
eventually render nanoparticles able to detect and kill 
cancer cells simultaneously
31
. 
Although there are certain crucial questions and many 
challenges remaining for the clinical development of 
nanoparticles, as more clinical data are available, further 
understanding in nanotechnology will certainly lead to 
the more rational design of optimized nanoparticles with 
improved selectivity, efficacy and safety
32
. Current 
knowledge regarding the safety of nanocarriers, 
however, is insufficient. The pharmacokinetic behavior 
of different types of nanoparticles requires detailed 
investigation, and a database of health risks associated 
with different nanoparticles should be created. 
Preliminary and complementary animal studies should 
be carried out to identify the risks associated with 
nanoparticle use, with particular attention paid to 
elimination processes. Furthermore, very little attention 
has been paid to environmental effects and the potential 
effects on the health of those manufacturing these 
particles. Considering the countless potential 
applications of nanoparticles in the health sector, 
particularly in cancer research, there is an urgent need 
for the development of safety guidelines by the 
government
33
. The emergence of Nanotechnology 
Research Centers, established in recent years (some of 
which are funded through the National Institutes of 
Health and the National Science Foundation), 
demonstrate the enthusiasm of investigators and granting 
agencies for the technology. In the next few years, many 
applications of nanotechnology will become 
commonplace within medical practice. Because these 
advancements will be incremental and will be initially 
derived from ongoing ‘wet science’ instead of scaled-
down machining and computing, they might, ironically, 
sometimes be too small to be noticed
34
. 
CONCLUSION  
The application of nanotechnology in the field of cancer 
nanotechnology has experienced exponential growth in 
the past few years. Nanoparticles provide opportunities 
for designing and tuning properties that are not possible 
with other types of therapeutic drugs and have shown 
they have a bright future as a new generation of cancer 
therapeutics. The multidisciplinary field of 
nanotechnology holds the promise of delivering a 
technological breakthrough and is moving very fast from 
concept to reality. 
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